Physician profile
Fred Chu
NPI 1932420478
$5,183.28
in general payments reported to CMS, 2019-2025
25 companies · $3,226 in 2025
The $3,226 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $272 · 2021: $128 · 2022: $128 · 2023: $480 · 2024: $500 · 2025: $3,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $1,205.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haag-Streit USA, INC. | $3,000.00 | 2025 | |
| Alcon Vision LLC | $424.55 | 2019-2025 | Argos, Hydrus Microstent, Clareon |
| Aerie Pharmaceuticals, INC. | $227.80 | 2019-2021 | |
| Abbvie INC. | $218.15 | 2022-2025 | Xen Glaucoma Treatment System |
| Bausch & Lomb Americas INC. | $162.50 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Glaukos Corporation | $158.88 | 2024 | |
| Allergan, INC. | $151.50 | 2019-2020 | |
| Ivantis, INC | $150.85 | 2019-2021 | |
| Alimera Sciences, INC. | $86.71 | 2023-2024 | Iluvien, Yutiq |
| Lombart Brothers, INC. | $86.43 | 2019 | |
| Apellis Pharmaceuticals, INC. | $71.29 | 2023-2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.67 | 2019-2021 | |
| Genentech USA, INC. | $48.50 | 2024 | Vabysmo |
| Ani Pharmaceuticals, INC. | $46.90 | 2024-2025 | Purified Cortrophin Gel |
| New World Medical,INC. | $45.76 | 2023-2025 | Kahook Dual Blade, Via360, Clearpath |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $40.68 | 2023-2024 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $32.28 | 2019 | |
| Biotissue Holdings INC. | $28.39 | 2023 | |
| Astellas Pharma US INC | $25.93 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $22.95 | 2022 | |
| Amgen INC. | $21.88 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $21.23 | 2023 | Tyrvaya |
| Horizon Therapeutics Plc | $17.27 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $15.95 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.